Geron(GERN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GERN Geron

Post-Mkt 12-19 17:39:25 EST

1.33

-0.01

-0.75%

盘后1.33

+0.000.00%

17:39 EST

High1.36	Low1.31	Vol11.80M
Open1.36	D1 Closing1.34	Amplitude3.73%
Mkt Cap849.01M	Tradable Cap710.33M	Total Shares638.36M
T/O15.68M	T/O Rate2.21%	Tradable Shares534.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GERN","market":"US","secType":"STK","nameCN":"Geron","latestPrice":1.33,"timestamp":1766178000000,"preClose":1.34,"halted":0,"volume":11798243,"hourTrading":{"tag":"盘后","latestPrice":1.33,"preClose":1.33,"latestTime":"17:39 EST","volume":1341748,"amount":1784583.6085624,"timestamp":1766183963197},"delay":0,"floatShares":534080710,"shares":638355275,"eps":-0.120126,"marketStatus":"Post-Mkt","change":-0.01,"latestTime":"12-19 17:39:25 EST","open":1.3583,"high":1.36,"low":1.31,"amount":15684376.595123202,"amplitude":0.037313,"askPrice":1.33,"askSize":3000,"bidPrice":1.31,"bidSize":405,"shortable":3,"etf":0,"ttmEps":-0.120126,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766192400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":838699200000,"exchange":"NASDAQ","adjPreClose":1.34,"preHourTrading":{"tag":"盘前","latestPrice":1.34,"preClose":1.34,"latestTime":"09:26 EST","volume":13222,"amount":17779.5625788,"timestamp":1766154379227},"postHourTrading":{"tag":"盘后","latestPrice":1.33,"preClose":1.33,"latestTime":"17:39 EST","volume":1341748,"amount":1784583.6085624,"timestamp":1766183963197},"volumeRatio":1.32613,"impliedVol":0.9972,"impliedVolPercentile":0.672},"requestUrl":"/m/hq/s/GERN/wiki","defaultTab":"wiki","newsList":[{"id":"2592418440","title":"Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2592418440","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592418440?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:30","pubTimestamp":1766093400,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., Dec.  18, 2025  (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective December 17, 2025, it granted st","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/18/3208202/35501/en/Geron-Corporation-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"2592818543","title":"Investor Says He 'Doubled' His Savings After Using ChatGPT in Stock Research – Shares Top 5 Stock Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2592818543","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592818543?lang=en_us&edition=fundamental","pubTime":"2025-12-19 02:05","pubTimestamp":1766081100,"startTime":"0","endTime":"0","summary":"Retail investors are increasingly using AI models and chatbots to find winning trades and beat the market. The use of AI tools to build stock portfolios has increased 46% year over year among retail investors, according to a survey by broker eToro Group Ltd.  released in October.In September, an investor on Reddit said he used ChatGPT for stock research and built a portfolio that delivered strong returns over a period of three months.\"I asked it to do a deep dive on 5 penny stocks that are most likely to return 10x value over the next 7-10 years,\" the Redditor said. \"On average, across these five stocks, I doubled some of my savings in three months.\". Let's break down the stocks in the portfolio.California-based biotechnology company Geron Corp.  was a loser in the portfolio, falling 15% in three months through Sept. 13. The stock is down 62% so far this year.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/18/Chinese-Gangs-Use-ChatGPT-In-US-Crypto-P.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/18/Chinese-Gangs-Use-ChatGPT-In-US-Crypto-P.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/25/12/49488107/investor-says-he-doubled-his-savings-after-using-chatgpt-in-stock-research-shares-top-5-stock-picks","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/12/49488107/investor-says-he-doubled-his-savings-after-using-chatgpt-in-stock-research-shares-top-5-stock-picks","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","BK4600","BK4585","GERN","BK4168","LAC","BK4023","SLDP","BK4124","BK4545","TLRY","BK4595","LU2360107671.USD","BK4547","LU1861217088.USD","BK4557",".IXIC","BITF","BK4561","BK4127","BK4596","BK4139","LU1861220207.SGD"],"gpt_icon":1},{"id":"2592937650","title":"Geron Corp - Begins Strategic Restructuring Plan - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592937650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592937650?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:02","pubTimestamp":1765918965,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM0L7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"2592293766","title":"Geron Corporation Announces Workforce Reduction and $18 Million Restructuring Charge","url":"https://stock-news.laohu8.com/highlight/detail?id=2592293766","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592293766?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:02","pubTimestamp":1765918940,"startTime":"0","endTime":"0","summary":"Geron Corporation has announced a strategic restructuring plan aimed at enhancing long-term value for patients and shareholders while improving financial discipline. Approved by the Board of Directors on December 10, 2025, the plan includes a workforce reduction of approximately one-third of its 260 employees. The company expects to incur around $18 million in restructuring charges, mainly from severance payments and related employee costs, with most cash payments anticipated by the end of the first quarter of 2026. The restructuring is expected to be substantially completed in early 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via EDGAR, the Elec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL273Nlw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"2590684516","title":"Geron Shares up 2.3% Premarket; Co Announces Strategic Restructuring Plan to Reduce Workforce by One-Third","url":"https://stock-news.laohu8.com/highlight/detail?id=2590684516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590684516?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:08","pubTimestamp":1765458520,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL4N3XH0XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"2590551633","title":"BRIEF-Geron Corporation Announces Strategic Restructuring Plan To Position The Company For Long-Term Value Creation","url":"https://stock-news.laohu8.com/highlight/detail?id=2590551633","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590551633?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:02","pubTimestamp":1765458140,"startTime":"0","endTime":"0","summary":"BRIEF-Geron Corporation Announces Strategic Restructuring Plan To Position The Company For Long-Term Value CreationDec 11 (Reuters) - Geron Corp GERN.O:GERON CORPORATION ANNOUNCES STRATEGIC RESTRUCTUR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA8TWLHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"2590515044","title":"Geron Corporation Cuts Workforce by One-Third in Strategic Restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515044","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590515044?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458059,"startTime":"0","endTime":"0","summary":"Geron Corporation has announced a strategic restructuring plan aimed at positioning the company for long-term value creation and improved financial discipline. The restructuring will result in approximately a one-third reduction of its current workforce of about 260 employees and is expected to be substantially complete in the first quarter of 2026. Geron anticipates that its full year 2026 operating expenses will be lower than those projected for 2025, with savings beginning in early 2026. The company's key objectives remain focused on driving commercial growth for RYTELO in the U.S., expanding its availability internationally, and advancing the Phase 3 IMpactMF trial. Restructuring charges will primarily consist of cash-based expenses, with further details to be disclosed in a forthcoming SEC filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL36rvC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GERN","IE00BGHQF748.EUR","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","NDAQ","SG9999014005.SGD","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2590551685","title":"Geron Corp - 2026 Operating Expenses Expected to Be Less Than 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590551685","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590551685?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA8TWLHY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"2590551508","title":"Geron Corp - Restructuring Plan to Reduce Workforce by One-Third","url":"https://stock-news.laohu8.com/highlight/detail?id=2590551508","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590551508?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA8TWLHY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GERN"],"gpt_icon":0},{"id":"2590516865","title":"Geron Corp - to Incur Cash-Based Restructuring Charges","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516865","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516865?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA8TWLHY:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"2590516814","title":"Geron Corp: Reduction in Geron's Current Workforce of About 260 Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516814","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516814?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA8TWLHY:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"2590150075","title":"Geron Corp: Restructuring Plan Is Expected to Be Substantially Complete in Q1 of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590150075","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590150075?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA8TWLHY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GERN"],"gpt_icon":0},{"id":"2590516858","title":"Press Release: Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516858","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590516858?lang=en_us&edition=fundamental","pubTime":"2025-12-11 21:00","pubTimestamp":1765458000,"startTime":"0","endTime":"0","summary":"Restructuring Supports RYTELO U.S. Commercial Strategy and Investment in Clinical Development. FOSTER CITY, Calif., Dec. 11, 2025  -- Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced a strategic restructuring plan intended to position the Company for long-term value creation for patients and shareholders and improve its financial discipline.Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO  is approved in the United States and the European Union for the treatment of certain adult patients with LR-MDS with transfusion-dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor R/R MF, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4022","R","GERN","BK4232"],"gpt_icon":0},{"id":"2589535183","title":"Geron Corporation Reports on IL-8 and TNF-Alpha Correlation with Survival in Myelofibrosis Patients Treated with Imetelstat","url":"https://stock-news.laohu8.com/highlight/detail?id=2589535183","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589535183?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:03","pubTimestamp":1765199024,"startTime":"0","endTime":"0","summary":"Geron Corporation has published a document detailing a post hoc analysis of the correlation between inflammatory cytokine levels and overall survival in patients with myelofibrosis who were relapsed or refractory to Janus-associated kinase inhibitor treatment and received imetelstat in the IMbark trial. The document describes results related to the effect of imetelstat on proinflammatory cytokines and its impact on clinical outcomes. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL3GcVRp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GERN"],"gpt_icon":0},{"id":"2589542353","title":"Geron Corporation Releases Phase 1b Trial Results on Imetelstat Plus Ruxolitinib for Myelofibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589542353","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589542353?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:03","pubTimestamp":1765199016,"startTime":"0","endTime":"0","summary":"Geron Corporation published a document on the IMproveMF Phase 1b clinical study evaluating imetelstat in combination with ruxolitinib for patients with myelofibrosis. The document includes information on study endpoints, enrollment status, site locations, and references to related clinical research. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL11PC7X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"2589590353","title":"Geron Corporation publishes analysis on imetelstat treatment-emergent cytopenias and clinical response in lower-risk myelodysplastic syndromes","url":"https://stock-news.laohu8.com/highlight/detail?id=2589590353","media":"Reuters","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589590353?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:03","pubTimestamp":1765199011,"startTime":"0","endTime":"0","summary":"Geron Corporation publishes analysis on imetelstat treatment-emergent cytopenias and clinical response in lower-risk myelodysplastic syndromes. Geron Corporation published a document analyzing the correlation between treatment-emergent cytopenias and clinical response with imetelstat in patients with lower-risk myelodysplastic syndromes. The document includes data from the IMerge trial and examines clinical consequences such as bleeding, infection, and febrile neutropenia. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on December 08, 2025, and is solely responsible for the information contained th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL4gR0J1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"2589596353","title":"Geron Unveils New Data Showing RYTELO Improves Outcomes in Lower-Risk MDS","url":"https://stock-news.laohu8.com/highlight/detail?id=2589596353","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589596353?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:03","pubTimestamp":1765198989,"startTime":"0","endTime":"0","summary":"Geron Corporation announced new data presented at the 67th American Society of Hematology  2025 Annual Meeting regarding its first-in-class telomerase inhibitor, RYTELO . The oral and poster presentations included pooled analyses from the IMerge study population, which suggested that treatment-emergent cytopenias may be associated with clinically meaningful outcomes, such as increases in hemoglobin and transfusion independence, in patients with lower-risk myelodysplastic syndromes . Additional analyses provided insights into imetelstat's safety profile and its potential in myelofibrosis and advanced MDS/AML. The company stated that these findings support the ongoing investigation of imetelstat as a treatment option for eligible patients with lower-risk MDS. The results have already been presented and are available on Geron's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLbzHk5Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","BK4588","SG9999014005.SGD","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","SG9999014021.USD","BK4139","SG9999014013.SGD","GERN","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2584925092","title":"Geron Q3 EPS USD -0.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2584925092","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584925092?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:38","pubTimestamp":1763570307,"startTime":"0","endTime":"0","summary":"Nov 05 (Reuters) - Geron Q3 net income USD -18.428 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 05-NOV-202512:00:46.94 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD8sPd7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GERN","BK4139"],"gpt_icon":0},{"id":"2581091664","title":"Wedbush Cuts Price Target on Geron to $5 From $6, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091664","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581091664?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:10","pubTimestamp":1762438205,"startTime":"0","endTime":"0","summary":"Geron (GERN) has an average rating of overweight and mean price target of $3.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GERN"],"gpt_icon":0},{"id":"1123358756","title":"Stock Track | Geron Soars 9.17% Pre-Market Following Q3 Earnings and Positive Analyst Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1123358756","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123358756?lang=en_us&edition=fundamental","pubTime":"2025-11-06 17:06","pubTimestamp":1762420017,"startTime":"0","endTime":"0","summary":"Geron Corporation (GERN) stock is experiencing a significant pre-market surge, jumping 9.17% following the release of its third-quarter earnings report and maintained buy ratings from analysts. This...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GERN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.geron.com","stockEarnings":[{"period":"1week","weight":-0.036},{"period":"1month","weight":0.2072},{"period":"3month","weight":0.0152},{"period":"6month","weight":-0.1126},{"period":"1year","weight":-0.6446},{"period":"ytd","weight":-0.6215}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.111018},{"month":2,"riseRate":0.321429,"avgChangeRate":-0.055097},{"month":3,"riseRate":0.464286,"avgChangeRate":0.066674},{"month":4,"riseRate":0.5,"avgChangeRate":0.013508},{"month":5,"riseRate":0.464286,"avgChangeRate":0.007843},{"month":6,"riseRate":0.482759,"avgChangeRate":0.074159},{"month":7,"riseRate":0.448276,"avgChangeRate":-0.014322},{"month":8,"riseRate":0.533333,"avgChangeRate":0.050328},{"month":9,"riseRate":0.3,"avgChangeRate":-0.011248},{"month":10,"riseRate":0.533333,"avgChangeRate":0.014873},{"month":11,"riseRate":0.466667,"avgChangeRate":0.036174},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.012111}],"exchange":"NASDAQ","name":"Geron","nameEN":"Geron"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Geron(GERN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Geron(GERN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Geron,GERN,Geron股票,Geron股票老虎,Geron股票老虎国际,Geron行情,Geron股票行情,Geron股价,Geron股市,Geron股票价格,Geron股票交易,Geron股票购买,Geron股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Geron(GERN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Geron(GERN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction